Related content

Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1805-1810

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012032067 and WO2012055846: two selective PI3Kδ inhibitors, which is GSK-2269557?

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 965-970

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 8, 2012-08 ,pp. : 971-976

Informa Healthcare

Access to resources Recommend Favorite

Selective PI3Kδ inhibitors, a review of the patent literature

By Norman Peter  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1773-1790

Informa Healthcare

Access to resources Recommend Favorite

A novel orally active inhibitor of HLE

By Varga M.   Kapui Z.   Batori S.   Nagy L.T.   Vasvari-Debreczy L.   Mikus E.   Urban-Szabo K.   Aranyi P.  

European Journal of Medicinal Chemistry, Vol. 38, Iss. 4, 2003-04 ,pp. : 421-425

Elsevier

Access to resources Recommend Favorite